OmniaBio in the News

A sampling of our latest coverage from media outlets and institutions.

Canadian CDMO OmniaBio launches new cell and gene therapy manufacturing facility. Xtalks.com, October 22, 2024.
OmniaBio opens cell and gene therapies manufacturing facility in Canada. Pharmaceutical Outsourcing, October 21, 2024.
New Hamilton plant keeps medicine production close to home. The Hamilton Spectator, October 19, 2024.
OmniaBio opens largest advanced therapy facility. The Pharma Letter, October 18, 2024.
OmniaBio Opens New cell and gene therapy manufacturing facility in Canada. Pharma Source, October 18, 2024.
AI-powered cell, gene therapy manufacturer ‘OmniaBio’ opens new facility in Hamilton, Ont. Global News, October 17, 2024.
OmniaBio announces the opening of its new commercial manufacturing facility. Canadian Manufacturing, October 17, 2024.
Canadian CDMO OmniaBio debuts new cell and gene therapy manufacturing facility. Fierce Pharma, October 17, 2024.
Canadian CDMO broadens CGT footprint with new $145M facility. Endpoints, October 17, 2024.
OmniaBio: Road to Canada’s largest cell and gene therapy CDMO. Invest Ontario, October 17, 2024
Serving tomorrow’s patients today. Business in Focus, October 2024.
Canada’s New Era in Cell and Gene Therapy. Next Generation Manufacturing Canada (NGen), October 10, 2024.
Somite Therapeutics and OmniaBio collaborate to advance cell therapy flagship programme. Manufacturing Chemist, October 1, 2024.
The Short Report: RESEARCH, TECH NEWS & COLLABORATION. Research Money, September 18, 2024.
FDA designations boost AI-driven cell therapy approach for Duchenne muscular dystrophy. BioPharmaReporter, September 17, 2024.
Event Recap: Toronto’s Regenerative Medicine Frontier. Toronto Region Board of Trade, August 23, 2024.
Coming to life at McMaster University. Hamilton City Magazine, June 3, 2024.
OmniaBio’s Impact and Future with Mitchel Sivilotti. Canadian SME Business Magazine, April 27, 2024.
Advancements in compact equipment and fuel options help the construction industry move toward a greener future. Heavy Equipment Guide, March 6, 2024.
NGen unveils 15 new advanced manufacturing projects at N3 Summit. Design Engineering, February 9, 2024.
Will AI Expertise Push Canada Forward As A Biopharma Hub? In Vivo, January 22, 2024.
Canadian Careers in Cell and Gene. The Medicine Maker, December 28, 2023.
Canadian biomanufacturing: Empowering global innovators in cell and gene therapy. ISCT Telegraft Hub, December 2023.
OmniaBio – McMaster Innovation Park. Award Magazine, December issue, 2023.
Multiplex Construction Canada and McMaster Innovation Park celebrate the OmniaBio project delivery. Canadian Manufacturing, November 29, 2023.
Can we build biotech labs fast enough? The Globe and Mail, November 28, 2023.
Creating a global ecosystem. Manufacturing in Focus, September issue, 2023.
New microcredentials to strengthen the talent pipeline for Canada’s biomanufacturing industry. U of T Engineering News, July 25, 2023.
Interview: Mitch Sivilotti. Next Great Big Ideas podcast, June 27, 2023.
How McMaster Innovation Park Is Advancing Cell and Gene Therapy. Health Insight, June 22, 2023.
Highlighting some of the cutting-edge companies in Ontario’s thriving biotechnology sector. Government of Ontario website, June 6, 2023.
CATTI Starts Up CGT Training Center at University of Guelph. PharmTech.com, May 17, 2023.
CATTI Opens Cell and Gene Therapy Training Center of Excellence. Contract Pharma, May 16, 2023.
OmniaBio: positioning Ontario to lead in a global biomanufacturing boom. Perspective, May 4, 2023.
Canada’s life science industry is poised to grow, and the real estate sector is mobilizing to support it. Real Estate News Exchange, April 25, 2023.
CCRM’s blueprint for a sustainable CGT ecosystem in Canada. BIOTECanada, April 23, 2023.
Canadian life science companies commercializing innovation in Hamilton. Perspective, page 26, March 24, 2023.
Catamaran Bio, OmniaBio Partner to Advance Allogeneic CAR-NK Cell Therapies. Contract Pharma, March 14, 2023.
A biomanufacturing site is coming to Canada’s Prince Edward Island. Endpoints News, February 14, 2023.
Nowhere to grow — Canadian life sciences companies look for lab space. Research Money, January 25, 2023.
Biggest Names in STEM Fly North For Talent. Site Selection magazine, January 2023 issue.
HAMILTON HIT AN ALLTIME RECORD FOR BUILDING PERMIT VALUES AT OVER $2.1-BILLION. Perspective, December 12, 2022.
Cell and Gene Champions Speak Out. The Medicine Maker, December 1, 2022 (2023 Special Supplement).
Medipost, OmniaBio to enhance cooperation for CDMO business. The Korea Economic Daily, December 1, 2022.
OmniaBio: Ready for the Global Biomanufacturing Boom. ISCT Telegraft Hub, November 2022 issue.
Avectas, CCRM and OmniaBio’s Collaboration to Accelerate the Manufacture of Edited iPSCs. Phacilitate website, November 30, 2022.
Avectas, CCRM & OmniaBio Expand Their Collaboration to Accelerate the Manufacture of Edited iPSCs Using SOLUPORE Technology. Drug Development & Delivery, November 30, 2022.
Race is on to claim share of biomanufacturing market. Investment Monitor, November 23, 2022.
Resolution Therapeutics And CCRM Sign Collaboration Agreement To Develop And Scale Up Manufacturing For iPSC-Derived Macrophage Cell Therapies. Outsourced Pharma, November 7, 2022.
Government Engagement Bodes Well For [Canadian] Life Sciences. MarketScreener, October 26, 2022.
NGen appuie la fabrication commerciale de thérapies cellulaires et géniques au Canada. CScience, October 11, 2022.
Innovation and commercialization in Southern Ontario. Synapse Consortium Brochure, Page 20. October 6, 2022.
Top 3 Trends in Cell and Gene Therapy. Cell & Gene. October 5, 2022.
NGen invests $10.5 M in Canadian Gov’t Cell-, Gene-Therapy Project. DCAT Value Chain Insights, September 29, 2022.
The Short Report – September 28, 2022. Research Money, September 28, 2022.
OmniaBio brings biomanufacturing muscle to Ontario. BIOTECanada Insights, Fall 2022 issue.
NGen Invests $10.5M to Support Commercial Scale Manufacturing of Cell & Gene Therapies in Canada. Contract Pharma, September 22, 2022.
CHCH Evening News at 6: OmniaBio and NGen feature. CHCH-TV, September 20, 2022.
Meet Mitch: The CEO leading Canada’s largest CDMO dedicated to manufacturing for CGTs. Signals blog, September 15, 2022.
CBRE Helps Launch Game-Changing Biomanufacturing Facility For Hamilton. CBRE website, September 7, 2022.
OmniaBio shapes the future of regenerative medicine. Invest Ontario website, July 27, 2022.
Multiplex to deliver McMaster Innovation Park’s flagship OmniaBio B, Canada’s first gene therapy facility. Multiplex Global website, July 19, 2022.
OmniaBio shares expansion plans with Hamilton investment partners at Collision Conference (with video). Invest in Hamilton website, June 23, 2022.
A big investment in CCRM’s OmniaBio, feds seek to advance digital charter, forging a new oil sands alliance, launching a climate impact accelerator, and more. Research Money, June 22, 2022.
OmniaBio, Medipost Ink Acquisition and Investment Deal. Contract Pharma, June 7, 2022.
Canada aims to get a slice of the growing global market for cell and gene therapies. Toronto Star, May 18, 2022.
McMaster Innovation Park wants more residential dev. Real Estate News EXchange, May 16, 2022.
What’s A CDMO And Why Do Biotech Startups Need them? Let’s Ask Canada. Crunchbase News, May 5, 2022.
Healthcare Is a Cost. But It’s Also a Business Opportunity. Canadian Business, April 26, 2022.
Gene therapy manufacturing coming to McMaster Innovation Park. The Bay Observer, April 1, 2022.
Ontario antes up $580M for C&G therapy plant in Hamilton. Endpoints News, April 1, 2022.
Ontario invests $40 million to grow global life sciences sector at Hamilton’s McMaster Innovation Park. Toronto Star, April 1, 2022
Ontario invests in $580 million gene and cell therapy facility in Hamilton. CHCH-TV, March 31, 2022.
New gene- and cell-therapy manufacturing facility to launch in Hamilton with $580-million commitment. The Globe and Mail, March 31, 2022.
WATCH: Ontario economic development minister to make announcement in Hamilton at 1:30 p.m. CHCH-TV, March 31, 2022.